Advanced Search
Contact | Corporate | Help

Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Sponsors:
  • Benaroya Research Institute
  • GlaxoSmithKline
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Female
Names:
  • Drug: bevacizumab and topotecan
Enrollment:
40

Additional information about NCT00343044.


SourceSolution © 2008-2012